E-64

M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavoglifozin) for Brazil and Mexico

Retrieved on: 
Tuesday, February 28, 2023
Blood pressure, Diabetes, Safety, Latin, Metformin, Partnership, SGLT2, Daewoong Pharmaceutical, Patient, Inhibitor, Glycated hemoglobin, MEXICO, E-64, Pharmaceutical industry, IQVIA

MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico.

Key Points: 
  • MEXICO CITY, Feb. 28, 2023 /PRNewswire/ -- M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 will have the rights to register and commercialize Envlo™ (Enavoglifozin) for Brazil and Mexico.
  • Phase 3 clinical trials have been performed on type 2 diabetes patients and its results demonstrated excellent effects in dropping blood sugar level drop.
  • The HbA1c decreased in the Enavogliflozin group by approximately 1% over the placebo group, which was statistically significant.
  • M8 Pharmaceuticals continues its commitment of bringing proven and innovative products to Latin American patients, and the agreement reinforces its commitment and capabilities in the area of cardiometabolism.

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Markets 2020-2021 & 2026: Focus on Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Pharmaceutical, DPP-4, Linagliptin, Vildagliptin, Bristol-Myers Squibb Co. v. Superior Court, IDF, Merck & Co., GlaxoSmithKline, Diabetes, Novartis, Growth, Prevalence, E-64, International Diabetes Federation, Anagliptin, Pharmaceutical industry, Fine chemical

The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.

Key Points: 
  • The dipeptidyl peptidase 4 (DPP-4) inhibitors aids in the release of insulin secretion in the patients' body and regulates the sugar levels in the body.
  • However, numerous side effects associated with the intake of dipeptidyl peptidase 4 (DPP-4) inhibitors in form of drugs challenge the growth of the market.
  • The global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented on the basis of drug type.
  • Geographically, the global dipeptidyl peptidase 4 (DPP-4) inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.